Lamivudine resistance in patients with chronic hepatitis B: Role of clinical and virological factors

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 7, 2007, Pages 1078-1085

  Thompson, Alexander J V ^a,b   Ayres, Anna ^b   Yuen, Lilly ^b   Bartholomeusz, Angeline ^b   Bowden, D Scott ^b   Iser, David M ^a   Chen, Robert Y M ^a   Demediuk, Barbara ^a   Shaw, Gideon ^a   Bell, Sally J ^a   Watson, Katrina J R ^a   Locarnini, Stephen A ^b   Desmond, Paul V ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

Chronic hepatitis B; HBe antigen; Lamivudine resistant mutation; Treatment; Viral load

Indexed keywords

HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROPORTIONAL HAZARDS MODEL; SEX RATIO; STRUCTURAL GENE; TREATMENT RESPONSE; VIREMIA; VIRUS GENE; VIRUS LOAD;

EID: 34347378741     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04630.x     Document Type: Article

References (31)

1. Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J. Hepatol. 2003 39 (Suppl. 1 S64 9.
2. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 1998 339 : 61 8.
3. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 1999 341 : 1256 63.
4. Tassopoulos NC, Volpes R, Pastore G et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999 29 : 889 96.
5. Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004 351 : 1521 31.
6. Chang TT, Lai CL, Chien RN et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 2004 19 : 1276 82.
7. Lai CL, Dienstag J, Schiff E et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 2003 36 : 687 96.
8. Fung SK, Lok AS. Management of hepatitis B patients with antiviral resistance. Antiviral Ther. 2004 9 : 1013 26.
9. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001 34 : 785 91.
10. Chang ML, Chien RN, Yeh CT, Liaw YF. Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B. J. Hepatol. 2005 43 : 72 7.
11. Zollner B, Petersen J, Schroter M, Laufs R, Schoder V, Feucht HH. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 2001 357 : 934 5.
12. Akuta N, Suzuki F, Kobayashi M et al. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J. Hepatol. 2003 38 : 315 21.
13. Moskovitz DN, Osiowy C, Giles E, Tomlinson G, Heathcote EJ. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. J. Viral Hepat. 2005 12 : 398 404.
14. Ciancio A, Smedile A, Rizzetto M, Lagget M, Gerin J, Korba B. Identification of HBV DNA sequences that are predictive of response to lamivudine therapy. Hepatology 2004 39 : 64 73.
15. Suzuki F, Tsubota A, Arase Y et al. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology 2003 46 : 182 9.
16. Lok AS, Hussain M, Cursano C et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000 32 : 1145 53.
17. Papatheodoridis GV, Dimou E, Dimakopoulos K et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005 42 : 121 9.
18. Locarnini S, McMillan J, Bartholomeusz A. The hepatitis B virus and common mutants. Semin. Liver Dis. 2003 23 : 5 20.
19. Kramvis A, Kew MC. The core promoter of hepatitis B virus. J. Viral Hepat. 1999 6 : 415 27.
20. Shin JW, Chung YH, Choi MH et al. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy. J. Gastroenterol. Hepatol. 2005 20 : 844 9.
21. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996 24 : 289 93.
22. Bell SJ, Lau A, Thompson A et al. Chronic hepatitis B: recommendations for therapy based on the natural history of disease in Australian patients. J. Clin. Virol. 2005 32 : 122 7.
23. Ayres A, Locarnini S, Bartholomeusz A. HBV genotyping and analysis for unique mutations. Methods Mol. Med. 2004 95 : 125 49.
24. Chan HL, Tsui SK, Tse CH et al. Epidemiological and virological characteristics of 2 subgroups of hepatitis B virus genotype C. J. Infect. Dis. 2005 191 : 2022 32.
25. Tacke F, Gehrke C, Luedde T, Heim A, Manns MP, Trautwein C. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants. J. Virol. 2004 78 : 8524 35.
26. Chen RY, Edwards R, Shaw T et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003 37 : 27 35.
27. Kobayashi S, Ide T, Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J. Hepatol. 2001 34 : 584 6.
28. Song BC, Cui XJ, Kim H. Hepatitis B virus genotypes in Korea: an endemic area of hepatitis B virus infection. Intervirology 2005 48 : 133 7.
29. Kao JH, Liu CJ, Chen DS. Hepatitis B viral genotypes and lamivudine resistance. J. Hepatol. 2002 36 : 303 4.
30. Nafa S, Ahmed S, Tavan D et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000 32 : 1078 88.
31. Zhou T, Saputelli J, Aldrich CE, Deslauriers M, Condreay LD, Mason WS. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Antimicrob. Agents Chemother. 1999 43 : 1947 54.